Blankinship & Foster LLC Buys New Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Blankinship & Foster LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,980 shares of the biopharmaceutical company's stock, valued at approximately $2,081,000. Regeneron Pharmaceuticals comprises 0.3% of Blankinship & Foster LLC's portfolio, making the stock its 28th biggest position.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Sachetta LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 10 shares during the last quarter. Rakuten Securities Inc. increased its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 19 shares during the period. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded down $32.03 during mid-day trading on Thursday, reaching $740.97. The stock had a trading volume of 923,616 shares, compared to its average volume of 555,558. The company has a market cap of $81.43 billion, a P/E ratio of 19.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12-month low of $735.95 and a 12-month high of $1,211.20. The business has a 50-day simple moving average of $860.87 and a 200 day simple moving average of $1,007.41.

Wall Street Analyst Weigh In

Several research firms recently commented on REGN. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research report on Friday, November 1st. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. JPMorgan Chase & Co. reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a research note on Thursday, October 24th. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada cut their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $1,099.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.